HighVista Strategies LLC Makes New $542,000 Investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

HighVista Strategies LLC bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 19,808 shares of the company’s stock, valued at approximately $542,000. HighVista Strategies LLC owned 0.07% of Dianthus Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock worth $2,095,000 after acquiring an additional 72,509 shares during the period. SG Americas Securities LLC grew its holdings in shares of Dianthus Therapeutics by 104.0% in the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after acquiring an additional 4,506 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of Dianthus Therapeutics by 281.9% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock worth $1,022,000 after acquiring an additional 29,159 shares during the period. Finally, American Century Companies Inc. grew its holdings in shares of Dianthus Therapeutics by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after acquiring an additional 8,473 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DNTH. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Oppenheimer upped their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Raymond James upped their price target on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Finally, Wedbush reduced their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Stock Down 0.5 %

Shares of Dianthus Therapeutics stock opened at $25.57 on Wednesday. Dianthus Therapeutics, Inc. has a fifty-two week low of $6.58 and a fifty-two week high of $33.77. The firm has a market cap of $756.87 million, a PE ratio of -10.23 and a beta of 1.74. The business’s fifty day moving average is $26.65 and its two-hundred day moving average is $26.53.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.